Shuttle Pharmaceuticals Reports Leadership and Compensation Changes
Ticker: SHPH · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
TL;DR
Shuttle Pharma's board and exec comp got a shake-up as of Aug 31, 2025.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on August 31, 2025, reporting changes in its board of directors and certain officers, as well as updates to compensatory arrangements. The filing indicates a shift in the company's leadership structure and potential adjustments to executive compensation.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, operational focus, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in executive and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- August 31, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific names and details of these changes are not provided in the excerpt.
Were there any changes in executive officer positions?
Yes, the filing mentions 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', suggesting potential changes in executive roles.
What is the nature of the updates to compensatory arrangements?
The filing notes 'Compensatory Arrangements of Certain Officers', indicating that there have been adjustments or new details regarding how certain officers are compensated.
When was this report filed with the SEC?
This 8-K report was filed as of September 5, 2025.
What is Shuttle Pharmaceuticals Holdings, Inc.'s principal executive office address?
The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 408 words · 2 min read · ~1 pages · Grade level 12.6 · Accepted 2025-09-05 16:35:21
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001641172-25-026719.txt ( ) — 197KB
- shph-20250831.xsd (EX-101.SCH) — 3KB
- shph-20250831_lab.xml (EX-101.LAB) — 33KB
- shph-20250831_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: September 5, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer 3